Intravenous epoprostenol for primary pulmonary hypertension [3]

New England Journal of Medicine

Volumn 334, Issue 22, 1996, Pages 1477-1478

  Schulze Neick, I ^a   Lange, P E ^a   Haas, N A ^a   Higenbottam, T ^a   Barst, R J ^a   Rubin, L J ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NITRIC OXIDE; PROSTACYCLIN; ANTITHROMBOCYTIC AGENT; VASODILATOR AGENT;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; DRUG EFFECT; NOTE; VASCULAR RESISTANCE;

EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; PLATELET AGGREGATION INHIBITORS; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0030014181     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199605303342214     Document Type: Letter

References (0)